Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 27;103(1):132–141. doi: 10.4269/ajtmh.19-0738

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The American Society of Tropical Medicine and Hygiene

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

Figure 3. — Overall per dose incidence of solicited injection-site (A) and general (B) adverse events during the 7-D post-vaccination period (TVC). DPIV+AS03_B = adjuvant system 03_B-adjuvanted inactivated tetravalent dengue virus vaccine; GI symtoms = gastrointestinal symptoms (nausea, vomiting, diarrhea, and/or abdominal pain); M = month; TVC = total vaccinated cohort; 0–1 M = participants receiving two doses of DPIV+AS03_B administered 1 M apart, at M0 and M1; 0–3 M = participants receiving two doses of DPIV+AS03_B administered 3 M apart, at M3 and M6; 0–1–6 M = participants receiving three doses of DPIV+AS03_B with the first two given 1 M apart and the third given 6 M after the first, at M0, M1, and M6. Error bars indicate 95% CIs.